<DOC>
	<DOCNO>NCT00031278</DOCNO>
	<brief_summary>The purpose study determine combination CPG 7909 Herceptin safe effective treatment metastatic breast cancer . RATIONALE : There preclinical data support hypothesis CPG 7909 may potentiate action Herceptin . This Phase I/II study design evaluate safety efficacy combination treatment CPG 7909 Herceptin patient metastatic breast cancer previously treat Herceptin chemotherapy . SCHEDULE : Patients receive CPG 7909 weekly six month .</brief_summary>
	<brief_title>Safety And Efficacy Study Of The Combination Of CpG 7909 And Herceptin In Patients With Metastatic Breast Cancer</brief_title>
	<detailed_description>Phase II part study initiate development plan modify route administration subcutaneous injection .</detailed_description>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>INCLUSION CRITERIA Inclusion Criteria Histologically confirm breast cancer metastasis . Tumor overexpression HER2 document either FISHpositive HER2/neu 3+ confirm immunohistochemistry . Patients must candidate single agent Herceptin treatment accord Herceptin® label . Exclusion Criteria Any prior therapy anthracycline + Herceptin® . Significant cardiovascular disease ( e.g. , NYHA class 3 congestive heart failure , myocardial infarction within past 6 month , unstable angina ; coronary angioplasty within past 6 month , uncontrolled atrial ventricular cardiac arrhythmia ) leave ventricular ejection fraction &lt; 50 % .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>Metastatic</keyword>
	<keyword>Breast</keyword>
	<keyword>Cancer</keyword>
	<keyword>immunotherapy</keyword>
	<keyword>CPG 7909</keyword>
</DOC>